The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...

Major stock indexes ended Wednesday trading virtually flat after an inflation report showed no surprises for investors.

BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

The acquisition would grant BioNTech full global rights to the promising bispecific antibody BNT327/PM8002, which was ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The deal, which is expected to close in Q1 2025, will give BioNTech (BNTX) full global rights to BNT327/PM8002, a PD-L1 x VEGF-A bispecific antibody that the companies believe has the potential to ...

German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect ...

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...